Adherence to the 2009 consensus guidelines for vancomycin dosing and monitoring practices: A cross-sectional survey of U.S. Hospitals

Pharmacotherapy

Volumn 33, Issue 12, 2013, Pages 1256-1263

  Davis, Susan L ^a,b   Scheetz, Marc H ^c,d   Bosso, John A ^e   Goff, Debra A ^f,g   Rybak, Michael J ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b HENRY FORD HOSPITAL   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

^d NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

clinical pharmacy services; survey; therapeutic drug monitoring; Vancomycin

Indexed keywords

VANCOMYCIN;

ARTICLE; BODY WEIGHT; CONSULTATION; CROSS-SECTIONAL STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG USE; HEALTH CARE QUALITY; HUMAN; MEDICAL PRACTICE; PRACTICE GUIDELINE; PROTOCOL COMPLIANCE; TOTAL QUALITY MANAGEMENT; UNITED STATES;

CLINICAL PHARMACY SERVICES; SURVEY; THERAPEUTIC DRUG MONITORING; VANCOMYCIN;

ANTI-BACTERIAL AGENTS; CROSS-SECTIONAL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GUIDELINE ADHERENCE; HEALTH CARE SURVEYS; HOSPITALS; HUMANS; INTERNET; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; UNITED STATES; VANCOMYCIN;

EID: 84889662137     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1327     Document Type: Article

References (38)

1. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2009; 1: 82-98.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin- resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 3: e18-55.
3. McKenzie C,. Antibiotic dosing in critical illness. J Antimicrob Chemother 2011; 66(Suppl 2): ii25-31.
4. Roberts JA, Lipman J,. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 3: 840-51; quiz 59.
5. Smith BS, Yogaratnam D, Levasseur-Franklin KE, Forni A, Fong J,. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012; 5: 1327-36.
6. Lomaestro BM,. Vancomycin dosing and monitoring 2 years after the guidelines. Exp Rev Anti Infect Ther 2011; 6: 657-67.
7. Truong J, Levkovich BJ, Padiglione AA,. Simple approach to improving vancomycin dosing in intensive care: a standardised loading dose results in earlier therapeutic levels. Intern Med J 2012; 1: 23-9.
8. Mohammedi I, Descloux E, Argaud L, Le Scanff J, Robert D,. Loading dose of vancomycin in critically ill patients: 15 mg/kg is a better choice than 500 mg. Int J Antimicrob Agents 2006; 3: 259-62.
9. Pea F, Viale P,. Should the currently recommended twice-daily dosing still be considered the most appropriate regimen for treating MRSA ventilator-associated pneumonia with vancomycin? Clin Pharmacokinet 2008; 3: 147-52.
10. Saugel B, Nowack MC, Hapfelmeier A, et al. Continuous intravenous administration of vancomycin in medical intensive care unit patients. J Crit Care 2013; 1: 9-13.
11. Wysocki M, Delatour F, Faurisson F, et al. Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 9: 2460-7.
12. Cataldo MA, Tacconelli E, Grilli E, Pea F, Petrosillo N,. Continuous versus intermittent infusion of vancomycin for the treatment of gram-positive infections: systematic review and meta-analysis. J Antimicrob Chemother 2012; 1: 17-24.
13. Ingram PR, Lye DC, Fisher DA, Goh WP, Tam VH,. Nephrotoxicity of continuous versus intermittent infusion of vancomycin in outpatient parenteral antimicrobial therapy. Int J Antimicrob Agents 2009; 6: 570-4.
14. Ingram PR, Lye DC, Tambyah PA, Goh WP, Tam VH, Fisher DA,. Risk factors for nephrotoxicity associated with continuous vancomycin infusion in outpatient parenteral antibiotic therapy. J Antimicrob Chemother 2008; 1: 168-71.
15. Vuagnat A, Stern R, Lotthe A, et al. High dose vancomycin for osteomyelitis: continuous vs. intermittent infusion. J Clin Pharm Ther 2004; 4: 351-7.
16. Bauer LA, Black DJ, Lill JS,. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998; 8: 621-5.
17. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO Jr,. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982; 4: 575-80.
18. Thomson AH, Staatz CE, Tobin CM, Gall M, Lovering AM,. Development and evaluation of vancomycin dosage guidelines designed to achieve new target concentrations. J Antimicrob Chemother 2009; 5: 1050-7.
19. Vance-Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC,. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993; 3: 436-40.
20. Young JF, Luecke RH, Pearce BA, et al. Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J Toxicol Environ Health A 2009; 8: 527-40.
21. Demirovic JA, Pai AB, Pai MP,. Estimation of creatinine clearance in morbidly obese patients. Am J Health Syst Pharm 2009; 7: 642-8.
22. Park EJ, Pai MP, Dong T, et al. The influence of body size descriptors on the estimation of kidney function in normal weight, overweight, obese, and morbidly obese adults. Ann Pharmacother 2012; 3: 317-28.
23. Celik I, Cihangiroglu M, Ilhan N, Akpolat N, Akbulut HH,. Protective effects of different antioxidants and amrinone on vancomycin-induced nephrotoxicity. Basic Clin Pharmacol Toxicol 2005; 5: 325-32.
24. Oktem F, Arslan MK, Ozguner F, et al. In vivo evidences suggesting the role of oxidative stress in pathogenesis of vancomycin-induced nephrotoxicity: protection by erdosteine. Toxicology 2005; 3: 227-33.
25. Cetin H, Olgar S, Oktem F, et al. Novel evidence suggesting an anti-oxidant property for erythropoietin on vancomycin-induced nephrotoxicity in a rat model. Clin Exp Pharmacol Physiol 2007; 11: 1181-5.
26. Bailie GR, Neal D,. Vancomycin ototoxicity and nephrotoxicity. A review. Med Toxicol Adverse Drug Exp 1988; 5: 376-86.
27. Farber BF, Moellering RC Jr,. Retrospective study of the toxicity of preparations of vancomycin from 1974 to 1981. Antimicrob Agents Chemother 1983; 1: 138-41.
28. Lodise TP, Lomaestro B, Graves J, Drusano GL,. Larger vancomycin doses (at least four grams per day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother 2008; 4: 1330-6.
29. Lodise TP, Patel N, Lomaestro BM, Rodvold KA, Drusano GL,. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 4: 507-14.
30. Vaidya VS, Ozer JS, Dieterle F, et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010; 5: 478-85.
31. Wong-Beringer A, Joo J, Tse E, Beringer P,. Vancomycin-associated nephrotoxicity: a critical appraisal of risk with high-dose therapy. Int J Antimicrob Agents 2011; 2: 95-101.
32. Bosso JA, Nappi J, Rudisill C, et al. Relationship between vancomycin trough concentrations and nephrotoxicity: a prospective multicenter trial. Antimicrob Agents Chemother 2011; 12: 5475-9.
33. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis 2012; 5: 621-9.
34. Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007; 2: R31.
35. van Hal SJ, Paterson DL, Lodise TP,. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob Agents Chemother 2013; 2: 734-44.
36. Cantu TG, Yamanaka-Yuen NA, Lietman PS,. Serum vancomycin concentrations: reappraisal of their clinical value. Clin Infect Dis 1994; 4: 533-43.
37. Forouzesh A, Moise PA, Sakoulas G,. Vancomycin ototoxicity: a reevaluation in an era of increasing doses. Antimicrob Agents Chemother 2009; 2: 483-6.
38. Shields RK, Martello JL, Potoski BA,. Is vancomycin ototoxicity a significant risk? Antimicrob Agents Chemother 2009; 10: 4572; author reply 72-3.